联馨药业：智改数转驱动传统中药企业质效提升？

Core Viewpoint - The pharmaceutical industry is undergoing a digital transformation driven by policy advancements and competitive dynamics, which is essential for upgrading the industry and enhancing core competitiveness [2]. Group 1: Industry Background - The digital transformation in the pharmaceutical industry is a key force for industrial upgrading and discovering new growth opportunities, supporting the implementation of the Healthy China strategy [2]. - The Ministry of Industry and Information Technology and other departments issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", marking a critical phase for the industry [2]. Group 2: Company Overview - Beijing Lianxin Pharmaceutical Co., Ltd. was established in 1999 and produces artificial musk, a national class I new drug, which has supported the production of over 500 traditional Chinese medicine varieties [3]. - The company is committed to innovation and modernization, actively promoting its "smart transformation and digital upgrade" strategy [3]. Group 3: Transformation Challenges - The pharmaceutical industry faces significant challenges in regulatory compliance, high difficulty, and long cycles, complicating the transformation process for companies like Lianxin [4]. - Key challenges include data silos, low data transparency, and a lack of digital transformation experience, which hinder the transition from traditional to modern production systems [4][5]. Group 4: Schneider Electric's Role - Schneider Electric recognizes the strategic significance of Lianxin's transformation and aims to optimize production, energy, and equipment management through digital upgrades [6]. - The company employs a phased approach to implement upgrades, utilizing tools like EcoConsult and the AVEVA PI System to enhance data integration and operational efficiency [7][8]. Group 5: Digital Transformation Implementation - The AVEVA PI System will break down data silos and facilitate proactive quality risk management by integrating various production-related data [8]. - The EMS+ system will establish a comprehensive energy management framework, optimizing energy efficiency and operational performance [9]. - The introduction of MES and automated batch control systems will enable lean production and refined management, ensuring consistent product quality [10]. Group 6: Significance of the Case - Schneider Electric's expertise in electrification, automation, and digitalization supports Lianxin's production line upgrades, enhancing quality, efficiency, and cost-effectiveness [11]. - Lianxin's digital transformation sets a benchmark in the industry, promoting sustainable and compliant smart pharmaceutical practices [12]. - The company aims to deepen digital applications and enhance decision-making quality, operational efficiency, and cost control, contributing to high-quality development in the pharmaceutical industry [12].